C4 Therapeutics, Inc. (CCCC) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US12529R1077
C4 Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 35.95 m USD |
| Operating income | -115.22 m USD |
| EBIT | -104.87 m USD |
| Net income | -104.99 m USD |
| Diluted EPS – continuing operations | -1.27 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
More stocks
- Ascencio (D) (ASCE.BR)
- Bemobi Mobile Tech S.A (BMOB3.SA)
- Hey-Song Corp (1234.TW)
- Suzhou Weizhixiang Food Co. Ltd. (605089.SS)
- Ningbo Xianfeng New Material (300163.SZ)
- Zhejiang Weigang Technology Co. Ltd. A (001256.SZ)
- CERUS CORP (CERS)
- Funko, Inc. (FNKO)
- Better Collective A/S (BETCO DKK.CO)
- Doright Co.Ltd. (300950.SZ)
- PARKE BANCORP, INC. (PKBK)
- Jilin Jinguan Electric Co Ltd Class A (300510.SZ)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.